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Abstract
Infection with influenza virus can result in massive pulmonary infiltration and potentially fatal immunopathology.
Understanding the endogenous mechanisms that control immunopathology could provide a key to novel adjunct therapies
for this disease. Here we show that the cytokine IL-27 plays a crucial role in protection from exaggerated inflammation
during influenza virus infection. Using Il-27ra2/2 mice, IL-27 was found to limit immunopathology, neutrophil accumulation,
and dampened TH1 or TH17 responses via IL-10–dependent and -independent pathways. Accordingly, the absence of IL-27
signals resulted in a more severe disease course and in diminished survival without impacting viral loads. Consistent with
the delayed expression of endogenous Il-27p28 during influenza, systemic treatment with recombinant IL-27 starting at the
peak of virus load resulted in a major amelioration of lung pathology, strongly reduced leukocyte infiltration and improved
survival without affecting viral clearance. In contrast, early application of IL-27 impaired virus clearance and worsened
disease. These findings demonstrate the importance of IL-27 for the physiological control of immunopathology and the
potential value of well-timed IL-27 application to treat life-threatening inflammation during lung infection.
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Introduction
Infection with highly pathogenic strains of influenza viruses,
such as the pandemic 1918 Spanish flu, which resulted in 30–50
million deaths, is still a major threat to health [1,2]. Pathological
findings suggest that the vigorous mobilization of innate and
adaptive arms of host immunity upon infection leads to
uncontrolled inflammation and potentially fatal lung injury [3].
Rapid leukocyte infiltration of the lung and a subsequent cytokine
storm involving the excessive production of inflammatory
cytokines and chemokines have been strongly implicated in
mediating lung immunopathology [3–5]. A better understanding
of the factors that regulate the balance between viral clearance,
tissue damage and resolution of inflammation is therefore
necessary [6].
Interleukin 27 (IL-27) might be one important player in this
context. The heterodimeric IL-27 belongs to the IL-12
superfamily and is composed of the Epstein-Barr virus
inducible gene-3 (EBI3) and the IL-27p28 subunit [7]. The
IL-27 receptor complex consists of IL-27Ra (WSX-1, TCCR)
and the gp130 subunit, and is expressed by a wide range of cell
types including T cells, monocytes, and neutrophils [8].
Initially, IL-27 was thought to promote TH1 responses because
of its ability to induce T-bet expression, thereby triggering the
upregulation of IL-12b2 receptor and IFN-c under some
conditions [9–11]. However, a series of subsequent studies
using in vivo models of infection or autoimmune diseases
provided evidence that its dominant function is rather to limit
immune-mediated pathology [12].
Mice deficient in IL-27 receptor displayed increased
immunopathology associated with overwhelming TH1 respons-
es following infection with a number of parasites and
intracellular bacteria [13–18]. Moreover, the lack of IL-27
receptor signaling resulted in augmented IL-17 production by
CD4+ T cells in several animal models, including experimental
autoimmune encephalomyelitis (EAE) [15,19,20]. Most studies
have characterized the ability of IL-27 to suppress CD4+ T cell
responses, but accumulating evidence suggests that the
regulatory function of IL-27 also extends to cells of the innate
immune system [8]. Consistent with its regulatory function,
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IL-27-mediated activation of STAT1, STAT3, STAT4 or
BLIMP-1 promotes IL-10 and suppresses IL-17 production by
CD4+ T cells [15,21–23]. Additionally, IL-27 induced the
expression of SOCS3 in CD4+ T cells, resulting in reduced
IL-2 secretion in these cells [24].
The role of IL-27 in influenza has not been comprehensively
studied. Liu et al. reported that influenza virus infection of
epithelial cells or leukocytes induced IL-27, which correlates with
increased serum levels of IL-27 in influenza patients [25].
Additionally, they showed a STAT1-dependent antiviral action
of IL-27 in vitro [25]. Mayer et al. reported that IL-27 induces IFN-
c in transgenic CD8+ T cells [26]. In contrast, Sun et al. found no
effect on T cell derived IFN-c but a reduced IL-10 production by
CD8+ T cells and increased leukocyte infiltration in infected Ebi-
32/2 or conditional Prdm12/2 mice [23,27].
We therefore investigated the impact of IL-27 and its receptor
IL-27Ra on immunopathology using the highly mouse patho-
genic [28] strain A/PR/8 (H1N1) and subsequently explored
the therapeutic potential of recombinant IL-27 (rIL-27) to treat
inflammatory lung disease in influenza. We found that, Il-
27ra2/2 mice exhibited increased mortality after influenza virus
infection due to exaggerated immunopathology, in conjunction
with augmented numbers of IFN-c or IL-17-producing CD4+
and CD8+ T cells, and a strongly increased neutrophil
infiltration. These effects were only partially attributed to
diminished IL-27-induced IL-10. Thus, IL-27 plays an impor-
tant role in limiting destructive inflammation, notably in the
resolving phase of infection. Well-timed treatment with rIL-27
improved lung injury and accelerated recovery without affect-
ing viral clearance. Our findings suggest that therapeutic
application of rIL-27 predominantly suppresses innate cell
recruitment but hardly affects the T cell response in the local
tissue. These data demonstrate that IL-27 has a unique role in
controlling immunopathology without impacting on host
defense, and might therefore represent a promising candidate
for immunomodulatory therapy of viral pneumonia.
Results
Impaired IL-27Ra signaling leads to increased mortality
following influenza virus challenge
To determine the role of IL-27 in shaping the immune response
against influenza virus, we first examined the kinetics of Il-27p28
and Ebi3 mRNA expression in the lungs of sublethally infected
C57BL/6 mice (Fig. 1A). While Ebi3 was constitutively expressed
and not significantly upregulated in the lungs and other organs
(Fig. 1B), Il-27p28 expression displayed a pronounced peak on
day 7 post-infection (d.p.i.), two days after the peak of the viral
load (Fig. 1C). Coinciding with the peak of Il-27p28 expression
was the maximal expression of Il-10 mRNA, which is consistent
with the assumption that IL-27 is an important inducer of IL-10
[15]. These mRNA data were confirmed at the protein level where
IL-27 and IL-10 peaked at 7 d.p.i (Fig. 1D). In contrast, the
inflammatory cytokines IL-12 and IL-23 were maximal already at
3 d.p.i (Fig. 1D). Thus, the expression kinetic of IL-27 in the
infected lungs follows, with some delay, the kinetic of the virus
load, being highest when virus is already declining and coming
down when immunopathology has resolved. This is compatible
with its role for dampening uncontrolled inflammation in a late
phase while initially allowing for a rapid start of immune defense.
To assess the impact of IL-27 on survival during influenza, we
challenged wild-type (WT) C57BL/6 or IL-27 receptor-deficient
(Il-27ra2/2) mice with 3000 egg infectious dose (EID) influenza
virus. Il-27ra2/2 mice displayed accelerated weight loss and
increased mortality following infection (Fig. 1E, F). Accordingly,
Il-27ra2/2 mice displayed a more severe lung pathology compared
to control mice at 7 d.p.i (using a slightly lower virus dose, 2500
EID, to allow survival of all mice) (Fig. 1G). Furthermore, Il-
27ra2/2 mice had increased capillary leakage in the respiratory
tract, leading to increased protein content in the bronchoalveolar
lavage (BAL) fluid of these mice (Fig. 1H). A higher neutrophil,
but not NK cell infiltration was observed in the lungs of Il-27ra2/2
mice at 8 d.p.i (Fig. 1I). Remarkably, the increase in immuno-
pathology and mortality in Il-27ra2/2 mice was not due to a
compromised viral elimination, as virus load was not significantly
different between Il-27ra2/2 and control mice (Fig. 1J). These
findings demonstrate that IL-27 plays a critical role in limiting
immunopathology during the later stages of infection.
Uncontrolled IFN-c and IL-17 T cell production in
influenza virus infected Il-27ra2/2 mice
Consistent with the ability of IL-27 to suppress TH1 and TH17
responses [15,29], influenza virus infected Il-27ra2/2 mice
exhibited significantly increased IFN-c levels in BAL fluid, lung
homogenate (Fig. 2A), and supernatants of enriched lymphocytes
from Il-27ra2/2 mice after polyclonal stimulation using PMA/
ionomycin (Fig. 2B). Accordingly, we detected increased numbers
of CD4+ and CD8+ T cells able to produce IFN-c upon re-
stimulation in the BAL and lungs of the Il-27ra2/2 mice (Fig. 2C).
In contrast, IFNa levels in the BAL of infected Il-27ra2/2 mice
were not different from WT animals (Fig. S1A). The results
suggest that IL-27 dampens IFN-c-production by T cells during
influenza.
Similar to the increased numbers of IFN-c+ T cells, we observed
augmented numbers of IL-17+CD4+, IL-17+CD8+ (Fig. 2D) and
TNF-a+CD4+ T cells (Fig. S1B) in the lungs of infected Il-27ra2/2
mice. A slight but not significant increase was also found for IL-
4+CD4+ T cells (Fig. S1C). Total numbers of CD4+ and CD8+ T
cells in the lungs at 9 d.p.i were not different between Il-27ra2/2
and WT mice (Fig. 2E). Taken together, these data demonstrate
Author Summary
Annual epidemics of influenza result in 3 to 5 million cases
of severe illness and approximately 300,000 deaths around
the world. Although most patients infected with normal
circulating influenza A viruses recover from the illness,
complications arise during infections with highly patho-
genic strains of the virus, resulting in increased mortality
associated with severe immunopathology and acute
respiratory distress. Previous studies suggested a major
contribution of the vigorous immune response to lung
damage. How the immune system constrains the negative
impact of inflammation might therefore be of significant
importance for future therapies. Our study in a mouse
model of influenza shows that the cytokine IL-27 plays a
crucial role in survival by protecting against lung damage.
Its actions include regulation of innate (neutrophil influx)
and adaptive (inflammatory cytokine production of T cells)
arms of immunity during the acute respiratory infection.
The data also suggest a therapeutic potential of IL-27, as
mice treated with recombinant cytokine at later stages of
infection exhibited decreased immunopathology and
showed improved survival. The findings uncover an
important role of IL-27 in limiting the collateral damages
of anti-viral immunity and provide initial evidence that
these mechanisms might be exploited for the manage-
ment of severe immunopathology after infection.
IL-27 and Influenza
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Figure 1. Absence of IL-27Ra leads to increased mortality and immunopathology during influenza. C57BL/6 mice were infected with a
sublethal dose influenza virus. Ebi3, Il-27p28 and Il-10 mRNA in the (A) lung at indicated d.p.i or (B) spleen, peripheral (pLN) and lung-draining (dLN)
lymph nodes of infected or uninfected C57BL/6 mice at 7 d.p.i. (C) Influenza virus polymerase (pa) mRNA expression or (D) cytokine concentration in
the lung homogenate of infected C57BL/6 mice were analyzed at indicated d.p.i. (E) Weight loss or (F) survival of infected Il-27ra2/2 (n = 9) or wild-
type (WT) C57BL/6 (n = 12) mice after challenge with 3000 EID influenza virus. Open circles in E represent remaining live Il-27ra2/2 mice (n = 2). (G)
Pathological scores of H&E-stained lungs of Il-27ra2/2 mice after 7 d.p.i. with 2500 EID influenza virus (H). Protein content in the BAL fluid of Il-27ra2/2
mice at 9 d.p.i. was quantified by BCA. (I) Representative FACS plots and numbers of lung-infiltrating neutrophils or NK cells of Il-27ra2/2 at 8 d.p.i. (J)
Viral pa mRNA in lungs of Il-27ra2/2 mice at 7 d.p.i was analyzed by qRT-PCR. Lung homogenates are a 20-fold dilution of homogenized whole lung
tissue. All data sets were pooled from at least two independent experiments. Values represent means 6 s.d. except for E, s.e.m. P values for F were
determined by log-rank survival test. P values for C, E, G, H, I and J were determined by unpaired two-tailed Student’s t test. ns, not significant.
doi:10.1371/journal.ppat.1004110.g001
IL-27 and Influenza
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that endogenous IL-27 limits the magnitude of effector cytokine
production by T cells during influenza.
Production of IL-10 by CD4+ T cells is induced by IL-27
Consistent with the role of IL-27 in inducing IL-10 production
by CD4+ T cells in other models [15,30–32], infected Il-27ra2/2
mice had decreased levels of IL-10 in the BAL fluid (Fig. 3A) and
in the supernatant of PMA/ionomycin-restimulated lymphocytes
(Fig. 3B). This decrease correlated with the impaired ability of Il-
27ra2/2 CD4+ T cells from infected mice to produce IL-10 after
in vitro restimulation with PMA/ionomycin (Fig. 3C). Moreover,
Il-27ra2/2 mice had reduced numbers of IL-10+IFN-c+ double-
positive cells, while total IFN-c+CD4+ T cells were increased,
resulting in a significantly reduced IL-10:IFN-c ratio in CD4+ T
cells of Il-27ra2/2 mice compared to WT animals (Fig. S2).
Although reduced, IL-10-producing CD4+ T cells were not
completely lacking in Il-27ra2/2 mice, suggesting that other
factors besides IL-27 contribute to the induction of IL-10 [33].
Numerous studies have established that IL-27 is signaling via
STAT factors such as STAT1, STAT3 and STAT4. Among these,
STAT4 has been shown to be involved in the induction of IL-10
production by CD4+ T cells [22,34]. STAT4 is, however, also the
main intermediate of IL-12 signaling. Sublethal influenza virus
infection of Stat42/2 mice resulted in significantly fewer lung-
infiltrating IL-10+IFN-c+CD4+ T cells; yet this was not the case in
IL-12p402/2 mice. Thus, IL-27 but not IL-12 is responsible for
STAT4 mediated induction of IL-10 (Fig. S3A, B). Viral loads in
the lungs of infected Stat42/2 mice at 9 d.p.i were not significantly
different to WT animals (Fig. S3C).
Thus, IL-10 becomes induced in IFN-c+CD4+ T cells during
influenza by IL-27, in part mediated via STAT4.
IL-27 regulates IL-17 via IL-10 and directly modulates IFN-
c production in T cells
We next determined whether IL-10 mediates the anti-inflam-
matory effects of IL-27. To this end, we infected Il-102/2 mice
Figure 2. Absence of IL-27Ra leads to increased numbers of IFN-c or IL-17-producing T cells in the respiratory tract. Il-27ra2/2 or
C57BL/6 mice were infected with 2500 EID influenza virus. At 9 d.p.i. IFN-c concentrations in the (A) BAL fluid and lung homogenate of Il-27ra2/2
mice or (B) supernatants of enriched Il-27ra2/2 lymphocytes after PMA/ionomycin restimulation was quantified by ELISA. Numbers of (C) IFN-c+ T
cells in the BAL or lungs and (D) IL-17+ T cells from the lung were analyzed by FACS after PMA/ionomycin restimulation. (E) Total numbers of CD4+ or
CD8+ T cells in the lungs and BAL of infected Il-27ra2/2 and WT mice. Lung homogenates are a 20-fold dilution of homogenized whole lung tissue. All
data sets were pooled from two independent experiments with similar results. P values were determined by unpaired two-tailed Student’s t test.
Values are means 6 s.d.
doi:10.1371/journal.ppat.1004110.g002
IL-27 and Influenza
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Figure 3. IL-27 directly modulates IFN-c production by T cells and indirectly regulates IL-17 response via IL-10. Il-27ra2/2 and C57BL/6
mice were infected with 2500 EID influenza virus. At 9 d.p.i, IL-10 levels in the (A) BAL fluid or (B) supernatants of enriched lymphocytes after PMA/
ionomycin restimulation were determined by ELISA. (C) Total numbers of IL-10+ T cells in the BAL were analyzed by FACS after PMA/ionomycin
IL-27 and Influenza
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with influenza virus and analyzed influenza peptide-specific IL-17
or IFN-c-producing T cells. Indeed, Il-102/2 mice had elevated
numbers of IL-17+CD4+ (Fig. 3D) and a slightly increased
numbers of IL-17+CD8+ T cells in the lungs (Fig. S4), similar to
that of infected Il-27ra2/2 mice. These results indicate IL-17
suppression is largely mediated via IL-10.
In contrast, the increased numbers of IFN-c-producing CD4+ or
CD8+ T cells in the respiratory tract of infected Il-27ra2/2 mice
were not observed in Il-102/2 mice (Fig. 3D and Fig. S4). These
findings were verified by blocking IL-10 signaling in vivo by
administration of an anti-IL-10 receptor antibody (aIL-10R; Fig.
S5A, B). Viral titers in the lungs of Il-102/2 mice were not
different to that of WT mice (Fig. S5C).
The ability of IL-27 to directly modulate IFN-c production in
CD8+ T cells was confirmed in vitro, where addition of rIL-27 to
the cultures strongly suppressed IFN-c and IL-2 production by
activated IFN-c+CD8+ T cells (Tc1 cells), even when IL-10R
signaling was blocked (Fig. 3E, F and Fig. S6). An IL-27-
dependent suppression of IFN-c and IL-2 in CD4+ T cells had
already been described previously [21].
These results demonstrate that IL-10-dependent effects only
partially account for IL-27 mediated suppression. Notably the IL-
10-independent effects on IFNc-production, but also on distinct
recruitment events (see below) might explain why deficiency in IL-
27 signaling has a strong impact on the disease course in influenza
while IL-10 deficiency has not (Fig. S7; for the latter see also
[35]).
Treatment with recombinant IL-27 alleviates
immunopathology when administered in a late phase of
the infection
Having demonstrated the pronounced role of IL-27 in
regulating immunopathology, we wondered whether this property
could be exploited for therapeutic purposes. In accordance with
the delayed endogenous production of IL-27, we administered
exogenous rIL-27 from 5–10 d.p.i. Indeed, this treatment regimen
resulted in decreased weight loss and accelerated recovery
(Fig. 4A), a striking improvement in lung immunopathology
(Fig. 4B), and in reduced capillary leakage as indicated by a lower
BAL fluid protein content (Fig. 4C). Notably, rIL-27 therapy did
not impair viral clearance (Fig. 4D). In line with this, the numbers
of CD8+ (Fig. 4E) or CD4+ (Fig. S8) T cells from the infected
respiratory tract producing either TNF, IL-17 or IFN-c upon
antigen-specific stimulation were not changed. Only a slight
decrease of secreted IL-17 (Fig. 4F) and increase of IL-10 levels
(Fig. 4G) was found in the BAL fluid. The protective effect of
treatment with rIL-27 was also found when mice were infected
with a lethal dose of influenza virus (Fig. 4H). We did not observe
significant effects of IL-27 treatment on the activity of virus-
specific CTLs as measured by the CD107 mobilization assay or
the fraction of IFN-c-producing CD8+ cells (Fig. S8).
To test whether the delayed kinetics of endogenous IL-27 is
relevant for an unhindered initial response to infection, we applied
exogenous rIL-27 from 1–7 d.p.i. (early phase). Mice treated
under this regimen exhibited stronger weight loss (Fig. 5A) and
reached the limits for euthanasia at 7 d.p.i. To assess the impact of
treatment on immunopathology and other parameters, all animals
were sacrificed at this time point. Although a diminished lung
histopathology was observed (Fig. 5B), a significantly higher viral
load was found (Fig. 5C). Impaired viral clearance was not due to
a suppressed T cell cytokine response as treated mice had
unchanged numbers of influenza peptide specific IL-17+ or IFN-c+
T cells in the respiratory tract (Fig. 5D). However, mice treated in
the early phase with rIL-27 had significantly reduced frequencies
of neutrophils (Fig. 5E) and monocytes, but not NK cells (Fig. 5F).
In our model, NK cells played a minimal role in viral clearance, as
NK1.1 cell-depletion did not influence viral loads (Fig. S9).
These findings suggest that systemic rIL-27 treatment during
the early stages of influenza has little impact on the local
antigen-specific T cell response, but suppresses neutrophil and
monocyte influx that are crucial for the control of infection at
this stage [28,36]. In contrast, treatment at a later time-point,
starting at the peak of viral load, did not impair viral clearance
but immunopathology and disease course were markedly
improved.
IL-27 treatment works by suppressing leukocyte
recruitment into the infected lungs
Therapeutic application of rIL-27 from 5–9 d.p.i. had surpris-
ingly little impact on the T cell compartment, but strongly
suppressed the accumulation of neutrophils (Fig. 6A), monocytes
and partially NK cells in the lung (Fig. 6B). We therefore
conclude that IL-27 can regulate innate cell trafficking indepen-
dently of any effect on T cell responses. Reduction of neutrophils,
but not of NK cells was mediated via IL-10, as is the reduction of
some chemokines in the BAL (Fig. S12)
Leukocyte accumulation in sites of inflammation is regulated by
chemokines and adhesion molecules governing both the entry and
exit from tissue. Indeed, rIL-27-treatment during influenza
reduced the levels of multiple chemokines in the BAL fluid
(Fig. 6C). To identify the cellular targets of IL-27-dependent
chemokine suppression, different leukocyte subsets from the lungs
of influenza virus infected mice were isolated and cultured
overnight in the absence or presence of rIL-27. IL-27 suppressed
chemokine production by CD11b+ or CD11c+ cells but had little
impact on NK cells or neutrophils (Fig. 6D). Especially the
chemokines KC (CXCL1), MIP-1b (CCL4) and RANTES
(CCL5), which are prototypic attractors of neutrophils, monocytic,
and lymphocytic cells, were suppressed. A similar suppression by
IL-27 was found for IL-1b or IL-6-induced chemokine production
by endothelial cells isolated from the lungs (Fig. S10).
To confirm the ability of IL-27 to suppress leukocyte
recruitment in the absence of a significant contribution from T
cells, we determined the impact of IL-27 treatment in the T cell-
independent zymosan-induced peritonitis model. Similar to
influenza, rIL-27 significantly reduced the levels of chemokines
in the peritoneal lavage as well as the numbers of neutrophils in
peritoneum and blood (Fig. 6E, F). As only minimal levels of IL-
17 are present in the peritoneal lavage (Fig. S11), this effect does
not rely on IL-17 suppression by IL-27. These data unravel a
restimulation. Representative FACS plots shown are gated CD4+ T cells from BAL. (D) Il-102/2 or C57BL/6 (WT) mice were infected with a sublethal
dose influenza virus. At 7 d.p.i., influenza virus peptide-specific IFN-c or IL-17-producing CD4+ T cells in the respiratory tract were assessed by FACS. (E
and F) Naive CD8+ T cells were activated with plate-bound anti-CD3 and anti-CD28 in Tc1 polarizing conditions in the presence or absence of rIL-27
and/or anti-IL-10 receptor blocking antibody (aIL-10R). After 3 days (d), cells were transferred to plates, then media was replenished with rIL-2, rIL-27
and/or aIL-10R antibody for additional 2 d, for a total of 5 d in culture. IFN-c or IL-2 production by Tc1 cells were analyzed by FACS. A to D were
pooled from two independent experiments with similar results. E and F represent data from three independent experiments with similar results. P
values were determined by unpaired two-tailed Student’s t test. Values are means 6 s.d. ns, not significant.
doi:10.1371/journal.ppat.1004110.g003
IL-27 and Influenza
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novel mode of action of IL-27 that is based on suppression of
innate cell recruitment into sites of inflammation.
Discussion
The tight regulation of both the induction and subsequent
down-regulation of inflammatory responses during influenza is
imperative in minimizing severe immunopathology. Infection with
highly pathogenic strains of influenza viruses results in increased
leukocytic pulmonary infiltrates and leads to the exaggerated
production of inflammatory cytokines (‘‘cytokine storm’’) that
causes massive inflammation with increased mortality [4,5,37].
Therefore, understanding the regulatory pathways during infec-
tion not only sheds light on the mechanisms controlling the
delicate balance of efficient viral clearance and disastrous
immunopathology, but also reveals potential therapeutic ap-
proaches to target resolution of inflammation [6]. Few studies
have evaluated the therapeutic potential of anti-inflammatory
agents in influenza; while broad-acting immunosuppressants such
as corticosteroids were found to worsen the disease, a combination
of antiviral therapy and anti-inflammatory non-steroidals inhibit-
ing cyclooxygenases (COX) improved survival in mice [38].
Similarly, targeting inhibitory pathways such as macrophage
CD200, PAR2 and endothelial S1P1 receptors have been found to
reduce immunopathology in influenza infection models [39–41]
Our findings suggest that IL-27 is a potential candidate for the
treatment of immunopathology, as endogenous IL-27 was found to
play a major role in dampening of exaggerated inflammation in
influenza while having little impact on virus elimination. The
absence of IL-27Ra signaling during acute virus infection
worsened immunopathology and disease course; this ultimately
resulted in increased mortality, despite controlled viral loads.
Additionally, increased neutrophil accumulation and augmented
IFN-c or IL-17 production by T cells were observed in the infected
Il-27ra2/2 mice while local IFNa levels appeared not to be
affected. These data are in agreement with a number of in vivo
models of bacterial or parasitic infection that underline a crucial
role of IL-27 in dampening inflammation [14,16–18,42].
That IL-27 acts in vivo predominantly as an anti-inflammatory
cytokine was not foreseen in the beginning, as several studies
Figure 4. Late-phase treatment with rIL-27 alleviates lung immunopathology. C57BL/6 mice were challenged with a sublethal (A to G) or
lethal (H) dose of influenza virus and treated daily with rIL-27 from 5–10 (A, H) or 5–9 (B to G) d.p.i. Non-treated control mice (NT) were injected with
PBS. (A) Weight loss of rIL-27-treated or NT mice. Arrows (Q) indicate points of treatment. At 9 d.p.i., (B) histological comparison of H&E-stained
lungs was performed, (C) protein content in the BAL fluid was measured by BCA, (D) viral pa mRNA expression in the lungs was measured by qRT-
PCR and (E) influenza virus peptide-specific cytokine production by CD8+ T cells was determined by FACS. Levels of (F) IL-17 and (G) IL-10 in the BAL
fluid or lung homogenates of late-treated or NT mice at 9 d.p.i. were measured by ELISA. Lung homogenates are a 20-fold dilution of homogenized
whole lung tissue. (H) Survival of mice treated with rIL27 or PBS from day 5–10 after challenge with a lethal dose of influenza virus. Values for weight
loss curves are data pooled from at least two independent experiments, representing the means 6 s.d. of the following numbers of mice per group:
day 1–9, n = 14; day 10–11, n = 7; day 12, n = 6. Data from B to H are pooled from at least two independent experiments with similar results. P values
were determined by unpaired two-tailed Student’s t test. Values are means 6 s.d. except for A, s.e.m.; ns, not significant. P values for H were
determined by log-rank survival test (n = 10).
doi:10.1371/journal.ppat.1004110.g004
IL-27 and Influenza
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demonstrated activating effects of IL-27, e.g. on the production of
IFN-c in vitro [9,10,43]. In an influenza model, Mayer et al.
reported that WT CD8+ T cells displayed higher IFN-c
production than IL-27Ra-deficient cells [26]. In this chimera
model, non-hematopoietic and half of the hematopoietic cells
responded to IL-27 so that only T cell- intrinsic effects of
deficiency were effective. In contrast, under the conditions of
global absence of IL-27Ra as used here, we observed increased
IFN-c levels and two-fold higher numbers of IFN-c+ T cells in the
infected respiratory tract of Il-27ra2/2 mice, in line with the
findings of the above-mentioned parasite infection models. We
assume, that the global effect of IL-27 in vivo involves a complex
network of cell types including myeloid cells or even non-hematopoi-
etic cells. In addition, timing and conditions might be crucial for the
Figure 5. rIL-27 treatment at an early stage of infection aggravates disease severity and impairs viral clearance. C57BL/6 mice were
challenged with a sublethal dose influenza virus then treated daily with rIL-27 from 1–7 d.p.i. Non-treated control mice (NT) were injected with PBS.
(A) Weight loss of rIL-27 treated (n = 5) or NT (n = 5) mice. Arrows (Q) indicate time of treatment. At 7 d.p.i., (B) histological scores of H&E-stained
lungs from treated or NT groups and (C) viral pa mRNA expression were determined. (D) Numbers of influenza virus peptide-specific IL-17 or IFN-c-
producing T cells, (E) influx of neutrophils, (F) monocytes and NK cells in the lungs at 9 d.p.i. were determined by FACS. Gated cells in FACS plots in e
indicate the percentage of neutrophils from total lung cells. Data from A are representative of two independent treatment experiments. Data from B
to F are pooled from at least two independent experiments. P values were determined by unpaired two-tailed Student’s t test. Values are means 6
s.d. except for A, s.e.m.; ns, not significant.
doi:10.1371/journal.ppat.1004110.g005
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quality of IL-27 effects, as we also found a direct, IL-10-independent
suppression of IFN-c and IL-2 in activated Tc1 cells by IL-27 in vitro.
Thus, the environmental context plays a significant role for the action
of IL-27 in vivo, and its impact on the innate response might dominate
over effects restricted to the T cell compartment. Indeed, the strong
increase in the number of lung-infiltrating neutrophils in the absence
of IL-27 signaling was one of the most impressive findings and appears
to be crucial for the worsened immunopathology.
Major effects of compromised IL-27 signaling were also found
on the number of IL-17 producing T cells. Both IFN-c and IL-17
have been reported to play a significant role for lung injury during
influenza [4,44,45]. IL-17 has been described as a major factor
boosting expansion, recruitment and activation of neutrophils by
inducing hematopoietic growth factors, chemokines and other
activating signals [46–48]. IL-27-dependent regulation of TH17
responses was reported to occur through a number of mechanisms
Figure 6. Late IL-27 treatment suppresses innate cell migration and chemokine production by CD11b+ and CD11c+ cells. C57BL/6
mice were challenged with a sublethal dose of influenza virus then treated daily with rIL-27 from 5–9 d.p.i. At 9 d.p.i., (A) numbers of neutrophils, (B)
monocytes or NK cells in the lungs were analyzed by FACS. Chemokine concentration in the (C) BAL fluid of late IL-27-treated influenza virus infected
mice. (D) Chemokine levels in cultures of CD11b+, CD11c+, NK (NK1.1+CD32) cells or neutrophils (Ly6G+CD11b+) isolated from influenza virus-infected
lungs after a 24 h treatment with rIL-27. (E) C57BL/6 mice were co-injected i.p. with zymosan (ZY) and rIL-27. Injection of zymosan only was used as
control. After 24 hours, chemokine levels in the peritoneal fluid were analyzed and (F) the numbers of neutrophils in the peritoneum and blood were
determined by FACS and. All data sets are pooled from at least two independent experiments with similar results. P values were determined by
unpaired two-tailed Student’s t test. Values in A, B, C, E and F are means 6 s.d.; D indicate means 6 s.e.m. *P,0.05; **P,0.01; nd, not detected.
doi:10.1371/journal.ppat.1004110.g006
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[15,20,49–51]. Here we provide evidence that suppression of IL-
17 is largely dependent on IL-10 acting as an intermediate, since
infected Il-102/2 mice displayed augmented numbers of IL-17+ T
cells, similar to that observed in Il-27ra2/2 mice. This is in
agreement with a previous study in which blocked IL-10R
signaling during high dose influenza virus infection resulted in
elevated numbers of IL-17+CD4+ T cells [35]. In contrast, IFN-c-
producing T cells were not affected by absence of IL-10.
Based on these data demonstrating the important role of IL-27
in controlling inflammation, we reasoned that application of rIL-
27 might be of value in situations in which exaggerated
immunopathology, rather than virus elimination, becomes a critical
issue for host survival as it is often the case in severe influenza.
Indeed, systemic application of daily doses of rIL-27 at 5–9 d.p.i
accelerated recovery and alleviated immunopathology by suppress-
ing the influx of neutrophils, monocytes and, to a lesser degree, NK
cells into the infected lungs of mice. Reduced infiltration appears to
be the major cause of the improved overall status of treated mice, as
large numbers of these cells can contribute to lethal lung damage by
producing inflammatory cytokines, chemokines and reactive oxygen
species, which results in the amplification of inflammatory signals
[4,5,37]. Again, the reduction in infiltrating neutrophils upon IL-27
therapy was largely dependent on IL-10 (Fig. S12). In contrast, the
reduced infiltration of NK cells was not dependent on IL-10,
underlining that not all effects of IL-27 are mediated by induced IL-
10 and that IL-27 has a broader suppressive effect than its
downstream-mediator IL-10. This latter conclusion is supported by
the finding that infected Il-27ra2/2, but not Il-102/2 mice
exhibited a more severe disease course compared to WT animals.
Surprisingly, the number and cytokine profile of influenza virus-
specific T cells in the lung was not significantly affected by
treatment with rIL-27. Moreover, virus elimination was not
impaired, if not even improved, upon treatment in the late phase.
Whether this is due to the reported induction of antiviral activity
by IL-27 that activates an interferon-induced antiviral protein
kinase-R (PKR) via STAT1 in human lung epithelial cells [25], or
whether destructive inflammation counteracts an efficient antiviral
defense, remains to be shown.
Although some reduction in the level of IL-17 and increase in
IL-10 was found in the BAL fluid upon treatment, these findings
suggest that rIL-27 applied systemically predominantly regulates
innate cell accumulation in the lungs rather than limiting the
activity of the adaptive arm of the immune system such as IFN-c
or IL-17 producing T cells within the inflamed tissue. An
explanation could be that local levels of IL-27 calculated for the
lung tissue of infected WT animals are two orders of magnitude
higher than plasma levels after systemic application of rIL-27 and
are therefore hardly increased upon treatment (Fig. S13). We
therefore propose that systemically applied rIL-27 predominantly
acts on cells exposed directly to blood or plasma exudate and/or
on innate cells before or during their journey to the inflamed lung.
To test the hypothesis that IL-27 treatment is able to suppress
the accumulation of neutrophils independent of T cells, we applied
rIL-27 in an acute model of TLR-induced sterile inflammation,
the zymosan-induced peritonitis model. In this model, T cells are
virtually absent in the inflammatory site, and IL-17 is hardly
detectable. Indeed, rIL-27 inhibited the accumulation of neutro-
phils also under these conditions.
As leukocyte trafficking is controlled by adhesion molecules and
chemokines presented on endothelial cells, we tested whether IL-
27 affects key molecules involved in the recruitment or retention of
innate leukocytes in influenza. Consistent with a role for IL-27 in
modulating the trafficking of neutrophils and monocytes, treat-
ment with rIL-27 reduced the production of neutrophil and
monocyte chemoattractants KC (CXCL1), MIP-1a (CCL3), and
RANTES (CCL5) produced in vitro by pulmonary monocytes
(CD11b+), alveolar macrophages/dendritic cells (CD11c+) or NK
cells isolated from infected lungs and resulted in reduced
chemokine levels in the BAL fluid of infected mice. Similar effects
were found with lung endothelial cells. These data complement
recent findings that IL-27 suppresses the response of macrophages
to TNF-a and IL-1 [52].
While the altered levels of chemokines in the BAL might affect
the retention of leukocytes in the alveolar space, the deposition of
chemokines on the endothelial surface by macrophages lining the
blood vessels would directly affect the adhesion and transmigration
of circulating leukocytes. Indeed, a major fraction of monocytic
cells in the lung is not situated in the parenchyma but sitting within
the vessel wall (‘‘marginal pool’’), rendering these cells sensitive to
the cytokines in the blood, including exogenously administered
cytokines [53,54]. In addition we found that the chemokine
production of endothelial cells upon stimulation with IL-1b or IL-
6 was suppressed by IL-27. Moreover, IL-27 has been reported to
directly affect adhesion and activation of neutrophils [55].
The expression of the IL-27p28 subunit in the influenza virus-
infected respiratory tract peaks at the later phase of infection when
viral titers are at a decline, which is consistent with the suggested
role of IL-27 in limiting the immune response. Interferons can
elicit IL-27 production as the Il-27p28 gene promoter contains an
IFN-stimulated response element region (ISRE), which becomes
activated through IRF-1 [56–58]. In contrast to the inflammatory
cytokines IL-12 or IL-23, which are rapidly produced by myeloid
cells, e.g. upon triggering TLR receptors, and accordingly found in
early time points in the influenza infection, the expression of IL-27
is turned on in a delayed fashion by the inflammatory
microenvironment and serves as a negative feedback mechanism,
thereby dampening the immune response in the later phase when
adaptive immunity is established and the risk of severe immuno-
pathology comes to the fore.
In line with this concept, we observed protective effects when
rIL-27 was administered in a later phase of infection, starting at
the peak of viral load when also the endogenous IL-27 production
is near its highest level. To test whether timing is crucial, we
additionally applied rIL-27 in the early phase of infection, starting
1 day after infection. Indeed, under these conditions IL-27
treatment also reduced leukocyte infiltration and immunopathol-
ogy, but simultaneously impaired virus elimination, resulting in a
worsened disease course. This suggests that interference with
leukocyte recruitment in the early phase of influenza aggravates
the infection, and the low level of endogenously produced IL-27 in
this early phase is appropriate to allow their unhindered rapid
activity in virus defense.
Indeed, previous studies have demonstrated that neutrophils are
essential for early host protection in influenza infection, as
neutrophil depletion before infection led to increased viral titers
and accelerated mortality [28,36]. The same was found for
alveolar macrophages [36]. While their mode of action is still
unknown, these studies suggest that neutrophils and macrophages
contribute to protection in the early phase. In the late phase,
depletion of neutrophils or macrophages was not affecting the
disease course, while even infection with a low pathogenic strain
was fatal in RAG-2cc2/2 mice lacking NK, T and B cells [28].
On the other side, recruited leukocytes have a major role in
immunopathology, e.g. by inducing apoptosis in epithelial cells
[59]. These findings are compatible with the paradigm that the
innate system contributes to early protection in viral infection,
while at later time points, antigen-specific T cells take over and
eliminate the virus.
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In conclusion, our study shows that endogenous IL-27 has a
crucial role in preventing a fatal disease course in influenza
where it acts to limit and resolve the inflammatory process while
allowing an unimpaired antiviral response (Fig. S14). Based on
its physiological role as a master factor regulating IL-10-
dependent as well as -independent anti-inflammatory mecha-
nisms, we here demonstrate that well-timed therapeutic appli-
cation of recombinant IL-27 can successfully counteract
detrimental immunopathology while keeping the antiviral
response intact. Combination of IL-27 treatment with anti-viral
or anti-microbial treatment might further expand the applica-
bility of this concept, especially when the role of IL-27 in
secondary bacterial infection [60] is appropriately taken into
account.
These data suggest that strategies to target natural multifunc-
tional pathways involved in the resolution of inflammation might
be a valuable alternative for the treatment of inflammation-
caused immunopathology and complement current therapeutic




Wild-type (WT) C57BL/6, BALB/c, Il-102/2, Il-12p402/2
and Stat42/2 mice were purchased from Taconic Farms, Charles
River, or The Jackson Laboratory. Il-27ra2/2 mice were
backcrossed more than nine generations to C57BL/6 mice [11]
and housed in the Department of Pathobiology at The University
of Pennsylvania, Philadelphia, USA. Mice were infected with
influenza A/PR/8/34 virus intranasally (i.n) while under dexdo-
mitor (0.5 mg/mL, Pfizer) and anti-mepazole (5 mg/mL, Pfizer)
anesthesia, or with light isofluorane. For sublethal infection with
influenza virus, BALB/c and Stat42/2 mice were infected with
12.5 plaque forming units (PFU), while C57BL/6, Il-102/2 and Il-
27ra2/2 mice were infected with 25 PFU or 2500 egg infectious
dose (EID). Survival assays with Il-27ra2/2 mice was performed
with 3000 EID. For experiments addressing the therapeutic
potential of rIL-27, 45 PFU of the virus were used as sublethal and
55 PFU as lethal dose. Infected mice were weighted daily and
assessed for clinical symptoms of infection. When reaching a
weight loss of .30%, mice were euthanatized. Animal care and
experiments were performed in accordance with the institutional
guidelines of German Federal Law and local authorities of Berlin
(LAGESO), or Animal Care and Use Committee of the University
of Pennsylvania.
Ethics statement
Animal procedures were performed in accordance with the
German ‘‘Tierschutzgesetz in der Fassung vom 18. Mai 2006
(BGBI.IS.1207)’’ and the guideline 2010/63/EU from the
European Union and the European Convention for the
protection of vertebrate animals used for experimental and
other scientific purposes. Animal protocols were approved by
the ethics committee and the Berlin state authorities (LAGeSo
Registration # G03310/08). Experiments performed at the
University of Pennsylvania were carried out in accordance with
the guidelines in the Guide for the Care and Use of Laboratory
Animals of the National Institutes of Health. The animal
protocol (# 802004) was approved by the Institutional Animal
Care and Use Committee (IACUC) of the University of
Pennsylvania, Philadelphia PA (Federal assurance #
FWA00004028; Office of Laboratory Animal Welfare assurance
# A3079-01).
Influenza virus
Influenza A/PR/8/34 virus was grown in the allantoic cavaties
of 11-day old embryonated chicken eggs or was purchased from
Charles River.
Bronchoalveolar lavage fluid and tissue preparation
Bronchoalveolar lavage (BAL) was obtained by flushing the
airways 36with 1 mL sterile PBS. Lungs (approximately 200 mg
of tissues) were mashed through a 70 mm cell strainer and
suspended in 10 mL of PBS/BSA. Lung lymphocytes were
enriched using a percoll gradient 40:70 (vol/vol). Erythrocytes
were lysed with an erylysis buffer (Sigma). BAL fluid and lung
homogenates were collected and stored at 280uC for ELISA and
BCA.
Leukocyte preparation for chemokine determination
CD11b+, CD11c+, NK1.1+CD32 (NK cells) and
Ly6G+CD11b+ (neutrophils) cells were isolated from infected
lungs of C57BL/6 mice at 5 d.p.i. and sorted by FACS. Cells
(16105/50 mL cRPMI) were incubated in the presence or absence
of rIL-27 (50 ng/mL) for 24 hours (h) without further stimulation
and chemokine concentrations in supernatants analyzed.
Assessment of lung injury, ELISA and multiple chemokine
detection
Total BAL fluid protein was measured using a bicinchoninic
protein assay (BCA) kit (Pierce Chemical). Cytokine or chemokine
concentration in BAL fluid, lung homogenates or cell cultures were
measured by enzyme-linked immunosorbent assay (BD Biosciences
or eBiosciences) or FlowCytomix multiple detection kit (eBioscience).
Zymosan-induced peritonitis
C57BL/6 mice were injected with zymosan (1 mg in 1 mL PBS)
intraperitoneally (i.p) with or without co-injection of rIL-27
(200 ng, R&D Systems). After 24 h, blood or 5 mL peritoneal
lavage (PBS) was obtained.
Lymphocyte culture
Naive CD8+ T cells (CD8+CD62L+) were isolated from pooled
splenocyte and lymph nodes using magnetic bead separation
(Miltenyi). For activation, purified CD8+ T cells (16106 cells per
mL) were cultured with plate-bound anti-CD3 (3 mg/mL; clone
145-2C11) and anti-CD28 (3 mg/mL; clone 37.51). CD8+ T cells
were supplemented with murine rIL-12 (5 ng/mL; eBioscience),
rIFN-c (20 ng/mL; eBioscience), and rIL-2 (10 ng/mL; R&D
Systems) plus anti-mouse IL-4 antibody (5 mg/mL; clone 11B11)
in complete RPMI media (RPMI 1640 (GibcoH) plus 10% FCS
(vol/vol) and antibiotics) for 3 days (d). After 3 d in culture, Tc1
cells were transferred to a plate without anti-CD3 and anti-CD28
and supplemented with fresh medium plus rIL-2 and cultured for
2 d for a total of 5 d in culture. In cases where rIL-27 (rIL-27) was
added or IL-10 receptor was blocked, the media were supple-
mented with rIL-27 (50 ng/mL; eBioscience) and/or anti-IL-10
receptor blocking antibody (aIL-10R) (40 mg/mL; 1B1-2). In some
experiments, cells were labeled with CFSE (Sigma) and cultured
under the same conditions as mentioned above.
T cell re-stimulation and intracellular cytokine staining
Intracellular cytokine staining (ICS) was performed as previ-
ously described (Hamada et al., 2009). Briefly, enriched lympho-
cyte samples were restimulated either with phorbol 12-myristate
13-acetate (PMA; 100 ng/mL) plus ionomycin for 4 h, or
a combination of immunodominant influenza virus peptides
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(Anaspec; Table S1) for 6 h in the presence of Brefeldin A
(10 mg/mL, Sigma). For analysis of CD107 expression, anti-
CD107a antibody (10 mg/mL) and anti-FcRc (10 mg/mL) was
added to the culture during 6 h peptide restimulation. Cells were
incubated with anti-FcRc receptor antibody prior to staining for
surface markers. Surface-labeled cells were fixed for 20 minutes
using 2% paraformaldehyde. Cytokines were stained using
fluorochrome-labeled anti-mouse monoclonal antibodies (mAbs)
in 0.1% saponin buffer for 20 minutes. Cells were washed and
resuspended in PBS/BSA then analyzed on a FACS Canto II (BD
Biosciences). Data were analyzed using Flowjo analysis
software (TreeStar). For FACS antibodies used, see supplemental
methods.
Quantitative reverse-transcription PCR
RNA was extracted using RNeasy Mini Kit with oncolumn
DNase digestion (Qiagen). cDNA was synthesized using Super-
scriptII Reverse Transcriptase (Invitrogen) with random hexa-
mers and oligo(dT) primers (Qiagen). Quantitative reverse-
transcription PCR (qRT-PCR) was performed using Platinum
SYBR Green qPCR SuperMix-UDG (Invitrogen) on a Strata-
gene MX3000 thermo cycler. For qRT-PCR primers used, see
Table S2.
In vivo treatments
Blockade of IL-10 signaling in vivo was achieved by administra-
tion of an anti-IL-10 receptor-specific mAb (aIL-10R; clone 1B1-
2) after 3 d (i.p., 1 mg in 200 mL PBS), 4 d (i.n., 0.15 mg in 30 mL
PBS) and 6 d.p.i (i.p., 1 mg in 200 mL PBS) [27]. rIL-27 (200 ng
in 100 mL PBS; eBioscience) was injected i.p. from 1–7 d.p.i.
(early) or 5–9/10 d.p.i. (late treatment). In parallel, mice were
injected solely with PBS (NT) as control. NK cell depletion was
performed by i.p injection of anti-NK1.1 depleting antibody
(500 mg in 500 mL; clone PK136) at 21, 1 and 5 d.p.i.
Histolopathological analysis
Lung samples were fixed with 4% formaldehyde, embedded in
paraffin and stained with hematoxylin and eosin (H&E). Images
were acquired using an AxioImager Z1 microscope equipped
with a charge-coupled device (CCD) camera (AxioCam MRm)
and processed with AxioVision software (all purchased from Carl
Zeiss MicroImaging, Inc.). H&E stained lung sections were
scored in a blinded manner as follows: (0) normal, (1) minor
perivascular inflammation around large blood vessels, (2)
moderate perivascular and peribronchial inflammation, (3)
increased perivascular and peribronchial inflammation, (4)
severe formation of perivascular, peribronchial, and interstitial
inflammation.
Antibodies and flow cytometry analysis
The following murine monoclonal antibodies (mAbs) were
purchased from BD Biosciences or eBioscience: CD4 (RM4-5),
Ly6-G (RB6-8C5), CD11c (N418), CD49b (pan-NK), CD11b
(M1-70), CD8a+ (53-6.7), CD62L (16A/MEL-14), CD3 (145-
2C11), IFN-c (AN18.17.24), IL-10 (JES5-A6E3), IL-17A (TC11-
18H10), TNF-a (MP6-XT22), CD107 (1D4B). CD31 (MEC13.3),
ICAM-1 (KAT1) and MHCII (M5/114) were obtained in house.
In certain cases, PI was added at 40 mg/ml to the cells
immediately prior to cell acquisition.
Statistical analysis
Data are means 6 s.d. or s.e.m. Statistical tests used include
Kaplan-Meier log-rank survival test, and unpaired two-tailed
Students t test. All P values.0.05 are considered not to be
significant.
Supporting Information
Figure S1 Similar levels of IFNa in BAL but increased
numbers of TNF-a+CD4+ T cells in the lungs of influenza
virus infected Il-27ra2/2 mice. Levels of IFNa in BAL (A),
and numbers of TNF-a and IL-4-producing CD4+ T cells in the
infected lungs of Il-27ra2/2 mice at 9 d.p.i. (B, C).
(PDF)
Figure S2 IL-10 production by CD4+ T cells during
influenza requires IL-27. Numbers of IL-10+IFN-c+ double-
positive (A), IL-10+ single-positive (C) CD4+ T cells and ratio
IL-10+/IFN-c+ (B) in the infected respiratory tract of Il-27ra2/2 mice
at 9 d.p.i.
(PDF)
Figure S3 Induction of IL-10 in CD4+ T cells partially
requires STAT4 but not IL-12. Frequencies and numbers of
IL-10+IFN-c+CD4+ T cells in the lungs of influenza virus infected
Stat42/2 (A) or Il-12p402/2 (B) mice. Viral load in Stat42/2 mice
(C).
(PDF)
Figure S4 IL-10 deficiency results in increased frequen-
cies of IL-17 but not IFN-c+ T cells in the lungs. Antigen-
specific IFN-c or IL-17-producing CD8+ T cells in the BAL and
lungs of infected Il-102/2 mice at 7 d.p.i.
(PDF)
Figure S5 Blocked IL-10 signaling during influenza
impaired IL-17, but not IFN-c expression in T cells.
The numbers of virus-specific IL-17 or IFN-c-producing CD4+
(A) or CD8+ (B) T cells in the lungs of infected WT mice were
assessed by FACS after blocking IL-10 signaling using an anti-IL-
10 receptor blocking-antibody (aIL-10R). Viral load in IL-102/2
mice (C).
(PDF)
Figure S6 IL-27 suppresses IFN-c production by CD8+ T
cells independently from IL-10 without inducing activa-
tion-induced cell death (AICD). (A) IL-27-dependent reduc-
tion of IFN-c production by Tc1 cells after 3 and 4 days in culture.
(B) CFSE staining of Tc1 cells in the presence of rIL-27.
(PDF)
Figure S7 Deficiency in IL-10 does not aggravate
disease course in influenza virus infected mice. Weight
loss comparison of Il-102/2 versus WT mice after sublethal
influenza virus infection.
(PDF)
Figure S8 rIL-27 treatment during the later phase of
influenza does not affect antigen-specific CD4+ T cell
cytokine responses, CD8+ (CTL) activity or levels of
virus-specific antibody. The numbers of IL-17, IFN-c or
TNF-a positive CD4+ T cells (A), of CD107 or IFNc positive
CD8+ T cells (B) in lungs and/or BAL upon peptide restimulation
as well as virus-specific antibody titers (C) in serum of infected
mice after late rIL-27 treatment.
(PDF)
Figure S9 Minimal role of NK cells in viral clearance
during influenza. Depletion of NK-cells (A) and its effects on
viral titers (B) in WT mice at 7 d.p.i.
(PDF)
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Figure S10 IL-27 suppresses IL-1 or IL-6-induced che-
mokine production in lung endothelial cells. Levels of IL-1
or IL-6 produced by sorted lung endothelial cells after rIL-27
treatment in vitro.
(PDF)
Figure S11 Minimal levels of IL-17 were found in
zymosan-induced peritonitis. IL-17 levels in the peritoneal
lavage of mice 24 h post injection with zymosan was measured by
ELISA.
(PDF)
Figure S12 Decreased neutrophil, but not NK cell
accumulation after late IL-27 treatment is dependent
on IL-10 and IL-10 is required for reduction of
chemokine production. (A) Frequencies of neutrophils and
NK cells of infected Il-102/2 mice treated with rIL-27. (B)
Frequencies of neutrophils and NK cells of infected WT mice after
anti-IL-10R antibody + rIL-27 treatment. (C) Chemokine levels in
the BAL fluid of Il-102/2 or WT mice infected with influenza
virus and treated with rIL-27.
(PDF)
Figure S13 Level of IL-27 in lung homogenates or
plasma of mice after late IL-27 treatment.
(PDF)
Figure S14 Control of inflammation by local and
systemic action of IL-27 in influenza. A cartoon depicting
the hypothetical scheme of interactions after rIL-27 treatment.
(PDF)
Table S1 Influenza virus peptides used for T cell
restimulation in vitro.
(PDF)
Table S2 Primers were used for qRT-PCR analysis.
(PDF)
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